Jacobson Mark L. 4
4 · Axsome Therapeutics, Inc. · Filed Jun 10, 2025
Insider Transaction Report
Form 4
Jacobson Mark L.
Chief Operating Officer
Transactions
- Sale
Common Stock
2025-06-09$110.44/sh−25,000$2,761,000→ 5,783 total - Exercise/Conversion
Common Stock
2025-06-09$8.02/sh+25,000$200,500→ 30,783 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-09−25,000→ 0 totalExercise: $8.02From: 2017-05-27Exp: 2026-05-27→ Common Stock (25,000 underlying)
Footnotes (4)
- [F1]Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $108.27 and $112.24.